Arbutus Biopharma ABUS
Ownership & positioning
Who holds it, who is betting against it, and where the big money is moving
Short-sale volume as % of daily volume
Large-order net flow, last 20 sessions
Net of large-order buying minus selling, in USD. Over this window: −$80.3K (10 inflow days, 10 outflow days).
Net flow by order size, last 20 sessions
Super/Big orders approximate institutional-size trades; Mid/Small approximate retail-size trades. Net buy minus sell value in each bucket, summed over the window.
The five largest holders on file together own 63.3% of shares outstanding.
Largest holders
By investor type
Reported short interest has risen from 9.33% to 10.04% of float over the last 6 biweekly reports (14 Aug 2026 to 30 Oct 2026).
Recent institutional activity
| Holder | Type | Period | Share change | New stake |
|---|---|---|---|---|
| Morgan Stanley Investment Management Inc. | Mutual Fund | 2026/Q3 | +1,560,566 | 12.2% |
| Barclays PLC | Public Company | 2026/Q3 | +1,191,316 | 0.8% |
| Los Angeles Capital Management LLC | Mutual Fund | 2026/Q3 | +780,849 | 0.9% |
| First Trust Advisors L.P. | Mutual Fund | 2026/Q3 | +696,258 | 0.5% |
| Morgan Stanley | Public Company | 2026/Q3 | +677,741 | 12.0% |
| Assenagon Asset Management S.A. | Mutual Fund | 2026/Q3 | +620,717 | 0.4% |
| Jane Street Group, LLC | Private Company | 2026/Q3 | +571,080 | 0.4% |
| BlackRock | Mutual Fund | 2026/Q3 | +565,661 | 9.3% |
| Boussard & Gavaudan Gestion S.A.S. | Mutual Fund | 2026/Q3 | +550,000 | 0.4% |
| Carrera Capital Advisors, LLC | Mutual Fund | 2026/Q3 | +324,977 | 0.4% |
| Nuveen Asset Management LLC | Insurance Company | 2026/Q3 | +278,951 | 0.2% |
| Nomura Holdings, Inc. | Public Company | 2026/Q3 | +1,637,081 | 1.1% |
| Goldman Sachs Asset Management, L.P. | Mutual Fund | 2026/Q3 | +1,602,576 | 0.9% |
| State Street Global Advisors | Mutual Fund | 2026/Q3 | +1,526,669 | 4.0% |
| Bank of America Corporation | Public Company | 2026/Q3 | +962,569 | 1.7% |
Institutional buy/sell activity by reporting period, largest moves first.
Insider transactions
| Date | Insider | Title | Transaction | Shares | Price | Held after |
|---|---|---|---|---|---|---|
| 30 Sep 2026 | Robert Beardsley | Independent Director | Sale to Issuer | -17,948 | $5.00 | 14,328 |
| 30 Sep 2026 | Roger Sawhney | Independent Director | Sale to Issuer | -17,142 | $5.00 | 13,683 |
| 30 Sep 2026 | Roivant Sciences Ltd. | Sale to Issuer | -8,967,383 | $5.00 | 29,880,079 | |
| 30 Sep 2026 | Lindsay Androski | Chairperson & CEO | Sale to Issuer | -24,655 | $5.00 | 19,682 |
| 30 Sep 2026 | Tuan Nguyen | Chief Financial Officer | Sale to Issuer | -48,081 | $5.00 | 38,382 |
| 17 Sep 2026 | Robert Beardsley | Independent Director | Derivative Exercise and Sale | -99,057 | $5.07 | 32,276 |
| 17 Sep 2026 | Robert Beardsley | Independent Director | Derivative Exercise and Retained | +32,276 | $3.20 | 32,276 |
| 17 Sep 2026 | Roger Sawhney | Independent Director | Derivative Exercise and Sale | -100,508 | $5.07 | 30,825 |
| 17 Sep 2026 | Roger Sawhney | Independent Director | Derivative Exercise and Retained | +30,825 | $3.34 | 30,825 |
| 17 Sep 2026 | Lindsay Androski | Chairperson & CEO | Derivative Exercise and Sale | -82,527 | $5.07 | 72,337 |
| 17 Sep 2026 | Lindsay Androski | Chairperson & CEO | Derivative Exercise and Retained | +44,337 | $3.20 | 72,337 |
| 17 Sep 2026 | Tuan Nguyen | Chief Financial Officer | Derivative Exercise and Sale | -206,637 | $5.07 | 159,963 |
| 17 Sep 2026 | Tuan Nguyen | Chief Financial Officer | Derivative Exercise and Retained | +86,463 | $3.49 | 159,963 |
| 7 Jun 2026 | Robert Beardsley | Independent Director | Other Derivative Acquisition | +78,800 | $4.24 | 78,800 |
| 7 Jun 2026 | Roger Sawhney | Independent Director | Other Derivative Acquisition | +78,800 | $4.24 | 78,800 |
| 1 Feb 2026 | Lindsay Androski | Chairperson & CEO | Other Acquisition | +28,000 | – | 28,000 |
| 1 Feb 2026 | Lindsay Androski | Chairperson & CEO | Other Derivative Acquisition | +71,700 | $4.39 | 71,700 |
| 1 Feb 2026 | Tuan Nguyen | Chief Financial Officer | Other Acquisition | +73,500 | – | 73,500 |
| 1 Feb 2026 | Tuan Nguyen | Chief Financial Officer | Other Derivative Acquisition | +188,400 | $4.39 | 188,400 |
| 3 Aug 2025 | Roger Sawhney | Independent Director | Other Derivative Acquisition | +157,600 | $3.34 | 157,600 |
From Form 4/Form 144 filings. Negative share counts are disposals (sales, gifts, or shares withheld for taxes); positive are acquisitions.
Short interest, by report
| Report date | Shares short | % of float | Days to cover |
|---|---|---|---|
| 30 Oct 2026 | 19,888,395 | 10.0% | 9.1 |
| 15 Oct 2026 | 24,566,591 | 12.4% | 4.3 |
| 30 Sep 2026 | 34,053,358 | 17.2% | 3.5 |
| 15 Sep 2026 | 18,484,910 | 9.3% | 5.0 |
| 31 Aug 2026 | 18,916,119 | 9.5% | 3.1 |
| 14 Aug 2026 | 18,456,085 | 9.3% | 15.1 |
No comments yet — be the first to weigh in on ABUS.
Sign in to join the discussion.